Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 2/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.31 |
| ▸ | CCR4 | P51679 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16292936 | 0.94 | CHRM2 (0.35) | CHRM2S1PR1ALDH1A1ALOX15TSHR | |
| SCHEMBL16293037 | 0.73 | CHRM2 (0.44) | CHRM2S1PR1ALDH1A1SIRT2HSP90AA1 | |
| SCHEMBL16293035 | 0.72 | CHRM2 (0.43) | CHRM2S1PR1SIRT2HSP90AA1HSP90AB1 | |
| SCHEMBL16293034 | 0.72 | CHRM2 (0.43) | CHRM2S1PR1SIRT2HSP90AA1HSP90AB1 | |
| SCHEMBL16292512 | 0.72 | CHRM2 (0.33) | CHRM2S1PR1HSP90AA1HSP90AB1 | |
| SCHEMBL15994215 | 0.71 | CHRM2 (0.42) | CHRM2S1PR1SIRT2HSP90AA1HSP90AB1 | |
| SCHEMBL18880300 | 0.71 | CHRM2 (0.42) | CHRM2S1PR1SIRT2HSP90AA1HSP90AB1 | |
| SCHEMBL16006930 | 0.70 | CHRM2 (0.41) | CHRM2S1PR1SIRT2HSP90AA1HSP90AB1 | |
| SCHEMBL16303335 | 0.69 | CHRM2 (0.41) | CHRM2S1PR1SIRT2HSP90AA1HSP90AB1 | |
| SCHEMBL16291618 | 0.69 | KDM5B (0.51) | CHRM2S1PR1ALDH1A1ALOX15L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961736-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2018-04-11 | — | — | EP | claimed |
| US-9650339-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-05-16 | — | — | US | claimed |
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | claimed |
| EP-2961736-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-3170811-A1 | ETHYL PYRIDINE-4-CARBOXYLATE COMPOUND AS INHIBITOR OF HISTONE DEMETHYLASES | Gilead Sciences, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| EP-3170811-A1 | ETHYL PYRIDINE-4-CARBOXYLATE COMPOUND AS INHIBITOR OF HISTONE DEMETHYLASES | Gilead Sciences, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| US-9650339-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650339-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-9221801-B2 | Inhibitors of histone demethylases | EPITHERAPEUTICS APS (DK) | 2015-12-29 | — | — | US | disclosed |
| US-9221801-B2 | Inhibitors of histone demethylases | EPITHERAPEUTICS APS (DK) | 2015-12-29 | — | — | US | disclosed |
| US-20140371214-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371214-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371214-A1 | INHIBITORS OF HISTONE DEMETHYLASES | KDM1B, KDM1A, KDM3A | CHRM2 3004/4885S1PR1 3369/4885ALDH1A1 1536/4885 |
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | KDM1B, KDM1A, KDM3A | CHRM2 3004/4885S1PR1 3369/4885ALDH1A1 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.